Last updated: March 22, 2026
What Is NDC 00955-1015?
NDC 00955-1015 refers to Eliquis (apixaban), manufactured by Bristol-Myers Squibb and Pfizer. It is an oral anticoagulant used for stroke prevention in atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT), and pulmonary embolism (PE). Approved by the FDA, Eliquis is classified as a factor Xa inhibitor.
Market Landscape
Market Size and Trends
- Global anticoagulant market was valued at USD 10.7 billion in 2022.
- Projected compound annual growth rate (CAGR): approximately 7% from 2023 to 2030 (Grand View Research, 2023).
- Increasing prevalence of atrial fibrillation, DVT, and PE drives growth.
- Healthcare shifts favor newer oral anticoagulants over warfarin, due to safety profile and convenience.
Competitive Position
- Eliquis is the leading DOAC (Direct Oral Anticoagulant) with about 40% market share in the United States (IQVIA, 2022).
- Main competitors: Xarelto (rivaroxaban) and Pradaxa (dabigatran).
- Patent expiration: Eliquis’s patent expires in 2029 for some formulations, opening generic opportunities.
Regulatory and Patent Considerations
- Patent status: Exclusivity until 2029; potential for generic erosion afterward.
- Orphan drug and market exclusivity periods are limited, emphasizing the importance of patent protection.
Price Trends and Projections
Current Pricing Data (As of Q1 2023)
| Formulation |
Average Wholesale Price (AWP) |
Estimated Out-of-Pocket Cost (with insurance) |
| 5 mg tablets, 60-count |
USD 370 |
USD 10–20 (co-pay; varies) |
| 2.5 mg tablets, 60-count |
USD 370 |
USD 10–20 |
Note: Price varies by pharmacy and insurance coverage.
Pricing Dynamics
- Brand Price Stability: Eliquis maintains stable pricing due to high demand and patent protection.
- Post-Patent Impact: Generic versions expected after 2029 could reduce prices by 20-30%, based on historical trends with biosimilars and direct competitors.
Price Projections (Next 5 Years)
| Year |
Estimated Price Range (USD) |
Key Factors |
| 2023 |
USD 370–390 |
Stable brand pricing |
| 2024 |
USD 350–380 |
Slight discounts for formulary inclusion |
| 2025 |
USD 340–370 |
Competitive pressures, supply chain stability |
| 2026 |
USD 330–360 |
Patent protection, competitive pricing from manufacturers |
| 2027 |
USD 320–350 |
Anticipation of generic approvals |
| 2028 |
USD 300–340 |
Market preparation for generic entry |
Market Entry and Price Erosion Post-Patent
- Generic Entry: Post-2029, generic apixaban could capture up to 80% of market share within two years.
- Price Decrease: Estimated to bring retail prices down to USD 100–150 per 60-count, reflecting 50-60% reduction.
Distribution and Payer Dynamics
- Payer Negotiations: Favorable negotiations and formulary placements could influence prices.
- Supply Chain: Manufacturer discounts, rebates, and distribution agreements heavily influence effective patient costs.
Strategic Considerations for Stakeholders
- Investors: Expect stable brand prices until patent expiry, with significant price erosion afterward.
- Manufacturers: Brand pricing supports high gross margins; preparing for patent expiration through pipeline diversification.
- Healthcare Providers: Shift towards lower-cost generics could influence prescribing habits.
Key Takeaways
- Eliquis (NDC 00955-1015) commands high market share in anticoagulation therapy.
- Current pricing remains stable but is subject to decrease post-2029 with generic entry.
- The broader anticoagulant market faces steady growth driven by aging populations and disease prevalence.
- Price erosion will significantly affect revenue streams for Eliquis after patent expiry.
- Market dynamics favor strategic planning by manufacturers and payers before generic competition intensifies.
FAQs
1. When does Eliquis patent protection expire?
Patent protection extends until 2029 for certain formulations, after which generics may enter the market.
2. How will generic entry impact Eliquis prices?
Prices could drop 50-60% within two years of generic availability, depending on market competition.
3. What are the main competitors to Eliquis?
Xarelto (rivaroxaban) and Pradaxa (dabigatran) remain primary competitors with similar indications.
4. How does insurance coverage affect patient costs?
Insurance and formulary placement influence copay amounts, often reducing out-of-pocket expenses.
5. Are there recent regulatory developments influencing Eliquis's market?
No major recent regulatory changes; patent expiry remains the key future factor affecting pricing.
References
- Grand View Research. (2023). Anticoagulants market size, share & trends analysis report.
- IQVIA. (2022). U.S. prescription drug market and market share data.
- FDA. (2019). Approval documents for Eliquis.
